A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- SOTIO Biotech AG
- Target Recruit Count
- 40
- Registration Number
- NCT06163391
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇧🇪Universitair Ziekenhuis Antwerpen (UZA), Edegem, Antwerp, Belgium
🇧🇪Institut Jules Bordet, Anderlecht, Brussels, Belgium
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- SOTIO Biotech AG
- Target Recruit Count
- 16
- Registration Number
- NCT05619172
- Locations
- 🇧🇪
Grand Hopital de Charleroi - Hopital Notre Dame, Charleroi, Belgium
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
🇪🇸Hospital Clinic de Barcelona, Barcelona, Spain
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- SOTIO Biotech AG
- Target Recruit Count
- 166
- Registration Number
- NCT05256381
- Locations
- 🇬🇪
Evex Hospitals - Caraps Medline, Tbilisi, Georgia
🇧🇪Institut Jules Bordet, Anderlecht, Belgium
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- SOTIO Biotech AG
- Target Recruit Count
- 200
- Registration Number
- NCT04234113
- Locations
- 🇫🇷
Institut Gustave Roussy, Paris, France
🇪🇸University Hospital Sanchinarro, Madrid, Spain
🇫🇷Hôpitaux Universitaires de Marseille Timone, Marseille, France
© Copyright 2024. All Rights Reserved by MedPath